## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT APPLICATION In re Application Inventor(s): Bales et al. Appl. No.: 10/786.627 2179 Art Unit:

Tuvetlien T. Tran Confirm, No.: 3071 Examiner: February 25, 2004 Filed:

Title: SYSTEMS AND METHODS FOR Customer No. 23910 PERSONALIZING A PORTAL

## TRANSMITTAL LETTER RE INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.56


Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir

It is requested that the information identified in this statement be considered by the Examiner and made of record in the above-identified application. This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56. If this is a continuation, divisional or continuation-in-part application, it is understood that the Examiner will consider all information which was considered by the Office in a parent application, MPEP \$609. Such information therefore is not listed herein unless it is desired that the information be printed on a patent issuing from the subject application.

| Enclosed with this statement are the following: |  |
|---|--|
| ✓   | Form PTO-1449. The Examiner is requested to initial the form and return it to the undersigned in accordance with M.P.E.P. $\$609$ .  |
| /   | As allowed under 37 C.F.R $\S$ 1.98(a)(2)(ii), no copies of the U.S. patents and U.S. patent application publications are enclosed, unless required by the office.   |
| _   | As allowed under 37 CFR §1.98(d), copies of cited documents noted with an asterisk are not enclosed because they were previously submitted in U.S. Patent Application No/, which is relied on for an earlier effective filing date under 35 USC §120, and which included an Information Disclosure Statement that complies with 37 CFR §1.98(a) through (c). |
| _   | A copy of an International Search Report dated for Application No A copy of an International Preliminary Examination Report dated for Application No   |

If any of the cited/submitted documents is in a foreign language, a concise explanation of relevance is provided pursuant to 37 C.F.R. §1.98(a)(3)(i). For foreign language documents cited in a search report by a foreign patent office, the requirement for a concise explanation of relevance is satisfied by the submission herewith of an English language version of the search report, MPEP \\$609A(3). If a written English-language translation of a non-English language document, or portion thereof, is within the possession, custody or control of, or is readily available to any individual designated in \$1,56(c), a copy of the translation accompanies this statement, 37 C.F.R. \$1,98(a)(3)(ii), and satisfies the requirement for a concise explanation of relevance, MPEP §609A(3).



- 37 C.F.R. §1.97(d). Although it may not qualify under subsection (b) or (c), this statement qualifies under 37 C.F.R. §1.97, subsection (d) because:
  - It is being filed on or before payment of the Issue Fee;

-- AND --

- (2) It is accompanied by a STATEMENT as set forth in 37 C.F.R. §1.97(e);
  -- AND --
- (3) It is accompanied by the \$180 fee set forth in 37 C.F.R. §1.17(p).
- PTA Statement under 37 C.F.R. §1.704(d). Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.
- 37 C.F.R. §1.97(e)(1). THE UNDERSIGNED ATTORNEY HEREBY STATES THAT each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
  - 37 C.F.R. §1.97(e)(2). THE UNIDERSIGNED ATTORNEY HEREBY STATES THAT no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patient office in a counterpart foreign application and, to the knowledge of the person signing this statement after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in §1.56(c) more than three months prior to the filing of this statement.
- ✓ Fee Authorization. The Commissioner is hereby authorized to charge any deficiencies or credit any overpayment to Deposit Account No. 06-1325.

Respectfully submitted,

FLIESLER MEYER LLP

Customer No. 23910 FLIESLER MEYER LLP 650 California Street, 14th Floor San Francisco, California 94108 Telephone: (415) 362-3800